XNASRNA
Market cap3.51bUSD
Jan 10, Last price
29.46USD
1D
-1.57%
1Q
-36.78%
IPO
1.94%
Name
Avidity Biosciences Inc
Chart & Performance
P/E
—
P/S
367.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
28.69%
Rev. gr., 5y
90.71%
Revenues
10m
+3.64%
Net income
-212m
L+25.52%
CFO
-119m
L-12.63%
Earnings
Feb 26, 2025
Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
IPO date
Jun 12, 2020
Employees
186
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 9,560 3.64% | 9,224 -1.09% | ||||
Cost of revenue | 247,259 | 189,524 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (237,699) | (180,300) | ||||
NOPBT Margin | ||||||
Operating Taxes | (4,918) | |||||
Tax Rate | ||||||
NOPAT | (237,699) | (175,382) | ||||
Net income | (212,220) 25.52% | (169,077) 44.05% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 60,547 | 344,779 | ||||
BB yield | -9.16% | -29.79% | ||||
| Debt | ||||||
Debt current | 7,278 | 3,105 | ||||
Long-term debt | 16,065 | 15,164 | ||||
Deferred revenue | 40,898 | 1,235 | ||||
Other long-term liabilities | 1,235 | |||||
Net debt | (572,008) | (592,709) | ||||
| Cash flow | ||||||
Cash from operating activities | (119,064) | (136,268) | ||||
CAPEX | (4,228) | (2,823) | ||||
Cash from investing activities | (130,070) | (189,955) | ||||
Cash from financing activities | 93,864 | 346,171 | ||||
FCF | (239,342) | (174,802) | ||||
| Balance | ||||||
Cash | 595,351 | 610,727 | ||||
Long term investments | 251 | |||||
Excess cash | 594,873 | 610,517 | ||||
Stockholders' equity | (570,631) | (361,235) | ||||
Invested Capital | 1,125,784 | 952,467 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 73,012 | 52,162 | ||||
Price | 9.05 -59.22% | 22.19 -6.65% | ||||
Market cap | 660,759 -42.91% | 1,157,475 17.54% | ||||
EV | 88,751 | 564,766 | ||||
EBITDA | (235,598) | (178,913) | ||||
EV/EBITDA | ||||||
Interest | 5,690 | |||||
Interest/NOPBT | ||||||